PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsCommentConfronting unproven stem cell treatments in Australia: The new regulation

BioNews

Confronting unproven stem cell treatments in Australia: The new regulation

Published 27 November 2017 posted in Comment and appears in BioNews 927

Author

Dr Patrick Foong

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).

Stem cell research holds tremendous promise for the treatment of a wide variety of illnesses and conditions, from spinal cord injury to autism. However, much more work is necessary to translate stem cell research into safe and effective therapies...

Stem cell research holds tremendous promise for the treatment of a wide variety of illnesses and conditions, from spinal cord injury to autism. However, much more work is necessary to translate stem cell research into safe and effective therapies. Many clinics are bypassing this crucial stage, advertising stem-cell based procedures on the internet despite little evidence for their safety or efficacy (see BioNews 908). Some patients, especially the acutely ill and desperate, are prepared to pay a high price for these stem-cell-based treatments.

The range of illnesses for which there are proven treatments based on stem cells is negligible. At present, the only established safe and effective stem-cell treatment is haematopoietic stem cell transplantation (HPC) transplantation; for decades, doctors have been using stem cells from bone marrow and umbilical cord blood to treat disorders of the blood and immune system such as leukaemia.

But other stem cell therapies are merely experimental. Just like a new drug, stem cell therapies must be assessed and meet stringent standards before obtaining the formal approval from regulatory bodies to be used to treat people. Thus, medical research into stem cells is still at infancy stages and more research is needed to create safe and effective treatments.

The grave concern is that stem cell therapies are being sold around the world, including Australia, before they have been proven safe and effective (see BioNews 921). There is direct advertising to consumers via the internet. There have been disturbing reports of baseless claims of cures; charlatans and adverse medical events. The potential risks include infection, allergic reactions, development of cancer, rejection of the cells by the patient's immune system and other complications that can be fatal. Also there is no evidence that these treatments will work. They may cause financial hardship as they are expensive and the procedures may involve repeat treatments. There may even be the cost of emergency medical care if something goes wrong. Undergoing unproven stem cell treatment may interfere with proven therapies and it can also disqualify the patient from participation in clinical trials.

Previously, these treatments are available mostly in developing countries with weak laws or lax enforcement such as China and India. However, these days, Australia too has some stem-cell businesses, growing to more than 60 such enterprises since 2011. Australia had among the world's highest concentration of stem-cell clinics, with websites advertising medical procedures and even anti-ageing therapies. Other developed countries that also engage in the direct-to-consumer marketing of stem-cell treatments are Ireland, Singapore, Germany, Italy, Japan, and the United States. Desperate people are at risk of becoming patients without the safeguards of a controlled clinical trial.

Australia's Therapeutic Goods Administration (TGA), which is responsible for ensuring that therapeutic goods are of an acceptable standard, introduced an exemption for certain types of biologicals including autologous therapies (cells and tissues that are removed from and applied to the same person, i.e., the donor and the recipient are the same person) in 2011. These cells may be treated, processed or purified after removal. As the cells come from the same person, there is a much lower chance of rejection of the cells by the patient's immune system. The exception was introduced because they were seen as an extension of medical practice and it was intended to exclude straightforward procedures from undue regulatory interference. Under the Therapeutic Goods (Excluded Goods) Order No1 of 2011, 'stem cell treatments may not be subject to regulation by TGA if they are human cells that are collected, processed and returned to the same patient, in a single course of treatment while under the clinical care and supervision of a registered medical practitioner'. However, these unproven stem cell-based therapies may be unsafe.

Recognising the potentially severe risks to human health and welfare posed by these stem cell-based therapies, TGA responded to this serious problem by conducting two consultations (one in 2015 and the other in 2016) with various stakeholders to seek public input to determine an appropriate regulatory framework. Four options were proposed for the future regulation of autologous human cell and tissue products. Option one maintains the status quo allowing providers to continue marketing unproven autologous stem cell directly to consumers. Options two, three and four prohibit the direct-to-consumer marketing of autologous stem cell but they differ according to the degree of manipulation that is permitted before regulatory exemption no longer applies.

Last month, TGA announced that changes to the law on autologous stem-cell therapies will be implemented in 2018. A transition period will permit providers some time to adjust to the new regulations. Some of the products will be subject to regulation as biologicals by the TGA with the level of control being determined by the risk posed to patient safety. This long-awaited and welcomed crucial step will place Australia into closer alignment with other jurisdictions such as the European Union and the US. When the new regulation is fully implemented, it is likely to be a successful effort to push back against unscrupulous doctors. While this is undoubtedly a progress, much would depend on the practical reality of the enforcement measures. It remains to be seen.

Related Articles

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
Comment
30 November 2020 • 3 minutes read

Panacea of 21st century for ovarian rejuvenation

by Dr Dusko Ilic

Are mesenchymal stem cells the new theriac of old, a medical concoction originally made by Greeks that was thought to cure all illnesses?...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
23 August 2019 • 2 minutes read

Mitochondria linked to stem cell transplant rejection

by Jen Willows

A new study has shown why stem cell transplants, even derived from the patient's own cells can be rejected...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
News
28 September 2018 • 2 minutes read

Dozens of firms discovered to sell untested stem cell treatments in Canada

by Martha Henriques

A total of 30 Canadian businesses have been found to provide untested and potentially unsafe stem cell treatments in a recent study...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 October 2017 • 2 minutes read

Commission demands reform on experimental cell therapies

by Jen Willows

The reputation of stem cell research is being undermined by unscrupulous clinics offering unproven therapies, says a report published last week...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
News
4 September 2017 • 2 minutes read

FDA crackdown on unproven stem cell therapies

by Rikita Patel

The US Food and Drug Administration intends to investigate the use of unproven stem cell therapies being offered in the country's clinics...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
News
31 August 2017 • 2 minutes read

Experts call for global action on unproven stem cell therapies

by Dr Lea Goetz

International experts are calling for global action on unproven and potentially dangerous stem cell therapies and their misleading marketing to the public...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 June 2017 • 2 minutes read

Two blood cancers treated successfully with immunotherapy

by Ebtehal Moussa

Two trials of a new gene therapy have successfully treated blood cancers in patients who were unresponsive to standard treatment...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Why germline genome editing may be discriminatory

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

FILM: 200 Years of Mendel – From Peas to Personalised Medicine

1 August 2022 • 4 minutes read

Women's Health Strategy plans reflect rising needs of same-sex female couples

25 July 2022 • 4 minutes read

Was the Women's Health Strategy worth the wait?

25 July 2022 • 4 minutes read

Why the UK should extend the 14-day rule to 28 days

25 July 2022 • 5 minutes read

200 Years of Mendel: From Peas to Personalised Medicine

8 August 2022 • 4 minutes read

Citizenship and same-sex parents – about time, Sweden!

8 August 2022 • 2 minutes read

FILM: 200 Years of Mendel – From Peas to Personalised Medicine

1 August 2022 • 4 minutes read

Women's Health Strategy plans reflect rising needs of same-sex female couples

25 July 2022 • 4 minutes read

Was the Women's Health Strategy worth the wait?

25 July 2022 • 4 minutes read

Why the UK should extend the 14-day rule to 28 days

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856